Lithium Triggers Opioid Peptide Release in the Brain by Disabling Their Self-Regulation System
Lithium stimulates the release of beta-endorphin, dynorphin, and met-enkephalin by disabling the autoreceptors that normally keep opioid release in check — with chronic use permanently inactivating some of these brakes.
Quick Facts
What This Study Found
Lithium releases all three opioid peptides by inhibiting autoreceptors. Chronic treatment permanently inactivates dynorphin and met-enkephalin autoreceptors through G-protein-dependent mechanisms.
Key Numbers
How They Did This
Rat hypothalamic slices were perfused with lithium and/or naloxone. Opioid peptide release was measured. Tetrodotoxin confirmed presynaptic action. Pertussis toxin tested G-protein involvement.
Why This Research Matters
This may partly explain how lithium stabilizes mood. By releasing opioid peptides and changing their regulation, lithium could affect mood, pain perception, and stress responses.
The Bigger Picture
This study offered a potential explanation for part of lithium's mood-stabilizing mechanism. If lithium permanently alters how the brain releases opioid peptides, this could contribute to its effects on mood, pain perception, and stress resilience. It connects psychiatric pharmacology to the endogenous opioid system.
What This Study Doesn't Tell Us
In-vitro hypothalamic slice study. Lithium concentrations used may not match therapeutic blood levels. The clinical significance of opioid release for bipolar disorder treatment is speculative.
Questions This Raises
- ?Does lithium's opioid-releasing effect contribute to its anti-suicidal properties?
- ?Are the mood-stabilizing and opioid effects of lithium separable?
Trust & Context
- Key Stat:
- Permanent autoreceptor inactivation Chronic lithium treatment (10 days) permanently disabled the autoreceptors controlling dynorphin and met-enkephalin release, but not beta-endorphin
- Evidence Grade:
- Preliminary in-vitro study using rat brain slices. Mechanistically detailed but the clinical relevance to bipolar disorder treatment is speculative.
- Study Age:
- Published in 1990. Lithium's mechanism of action remains incompletely understood, and its interaction with the opioid system is one of many proposed pathways.
- Original Title:
- Stimulation of hypothalamic opioid peptide release by lithium is mediated by opioid autoreceptors: evidence from a combined in vitro, ex vivo study.
- Published In:
- Neuroscience, 36(3), 691-7 (1990)
- Authors:
- Burns, G, Herz, A(14), Nikolarakis, K E(4)
- Database ID:
- RPEP-00148
Evidence Hierarchy
Frequently Asked Questions
What are autoreceptors?
Autoreceptors are self-regulating sensors on nerve terminals. When opioid peptides accumulate, autoreceptors detect this and reduce further release — acting as a brake. Lithium disables this brake, allowing more opioid peptide release.
Could lithium's opioid effects explain its mood-stabilizing action?
Potentially in part. Opioid peptides influence mood, pain perception, and stress resilience. By permanently altering their release regulation, lithium may contribute to emotional stability — though its mood-stabilizing effects likely involve multiple pathways.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00148APA
Burns, G; Herz, A; Nikolarakis, K E. (1990). Stimulation of hypothalamic opioid peptide release by lithium is mediated by opioid autoreceptors: evidence from a combined in vitro, ex vivo study.. Neuroscience, 36(3), 691-7.
MLA
Burns, G, et al. "Stimulation of hypothalamic opioid peptide release by lithium is mediated by opioid autoreceptors: evidence from a combined in vitro, ex vivo study.." Neuroscience, 1990.
RethinkPeptides
RethinkPeptides Research Database. "Stimulation of hypothalamic opioid peptide release by lithiu..." RPEP-00148. Retrieved from https://rethinkpeptides.com/research/burns-1990-stimulation-of-hypothalamic-opioid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.